title: Switching patients from blinded study drug to warfarin at the end of the ENGAGE AF-TIMI 48 trial: setting a new standard.
authors.affiliation: David Braley Cardiac, Vascular, & Stroke Research Institute, Hamilton General Hospital, Hamilton, Ontario, Canada; Hamilton General Hospital, Hamilton, Ontario, Canada; Department of Medicine, McMaster University, Hamilton, Ontario, Canada. Electronic address: eikelbj@mcmaster.ca.
authors.forename: John W
authors.initials: JW
authors.lastname: Eikelboom
authors.affiliation: David Braley Cardiac, Vascular, & Stroke Research Institute, Hamilton General Hospital, Hamilton, Ontario, Canada.
authors.forename: Thomas
authors.initials: T
authors.lastname: Vanassche
authors.affiliation: David Braley Cardiac, Vascular, & Stroke Research Institute, Hamilton General Hospital, Hamilton, Ontario, Canada; Hamilton General Hospital, Hamilton, Ontario, Canada; Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
authors.forename: Stuart J
authors.initials: SJ
authors.lastname: Connolly
mesh_terms: D000925:Anticoagulants / Q000008:administration & dosage*; D001281:Atrial Fibrillation / Q000188:drug therapy*; D057915:Drug Substitution / Q000379:methods*; D005260:Female; D006801:Humans; D008297:Male; D009203:Myocardial Infarction / Q000188:drug therapy*
chemical_list: D000925:Anticoagulants
keywords: apixaban; atrial fibrillation; edoxaban; rivaroxaban; warfarin